Humoral Immunogenicity of mRNA Booster Vaccination after Heterologous CoronaVac-ChAdOx1 nCoV-19 or Homologous ChAdOx1 nCoV-19 Vaccination in Patients with Autoimmune Rheumatic Diseases: A Preliminary Report
Open Access
Abstract
Immunogenicity data on the mRNA SARS-CoV-2 vaccine booster after completing a primary series vaccination, other than the mRNA vaccine, in patients with autoimmune rheumatic diseases (ARDs) is scarce. In this study, we reported the humoral immunogenicity of an mRNA booster 90–180 days after completing heterologous CoronaVac/ChAdOx1 nCoV-19 (n = 19) or homologous ChAdOx1 nCoV-19 (n = 14) vaccination by measuring the anti-SARS-CoV-2 receptor binding domain (RBD) IgG levels at one and three months after mRNA booster vaccination. This study included 33 patients with ARDs [78.8% women; mean (SD) age: 42.9 (10.6) years]. Most patients received prednisolone (75.8%, mean [IQR] daily dose: 7.5 [5, 7.5] mg) and azathioprine (45.5%). The seropositivity rates were 100% and 92.9% in CoronaVac/ChAdOx1 and ChAdOx1/ChAdOx1, respectively. The median (IQR) anti-RBD IgG level was lower in the ChAdOx1/ChAdOx1 group than in the CoronaVac/ChAdOx1 group (1867.8 [591.6, 2548.6] vs. 3735.8 [2347.9, 5014.0] BAU/mL, p = 0.061). A similar trend was significant in the third month [597.8 (735.5) vs. 1609.9 (828.4) BAU/mL, p = 0.003]. Minor disease flare-ups occurred in 18.2% of the patients. Our findings demonstrated satisfactory humoral immunogenicity of mRNA vaccine boosters after a primary series, with vaccine strategies other than the mRNA platform. Notably, the vaccine-induced immunity was lower in the ChAdOx1/ChAdOx1 primary series.Keywords
Funding Information
- Faculty of Medicine, Prince of Songkla University (64-092-1)
This publication has 40 references indexed in Scilit:
- Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2Annals of Internal Medicine, 2021
- Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppressionAnnals of the Rheumatic Diseases, 2021
- Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre studyAnnals of the Rheumatic Diseases, 2021
- Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory diseaseAnnals of the Rheumatic Diseases, 2021
- Methotrexate Hampers Immunogenicity to BNT162b2 mRNA COVID-19 Vaccine in Immune-Mediated Inflammatory DiseasemedRxiv, 2021
- COVID-19 vaccines: modes of immune activation and future challengesNature Reviews Immunology, 2021
- Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidatesEmerging Microbes & Infections, 2021
- What about the original antigenic sin of the humans versus SARS-CoV-2?Medical Hypotheses, 2020
- Response of transplant recipients to influenza vaccination based on type of immunosuppression: A meta-analysisSaudi Journal of Kidney Diseases and Transplantation, 2015
- DISQUISITIONS ON ORIGINAL ANTIGENIC SINJournal of Experimental Medicine, 1966